Alzheimer's Disease

ClinicalAugust 4, 2026

Study on Transcranial Pulse Stimulation for Alzheimer's Disease Safety and Efficacy

The study aims to assess the safety and effects of Transcranial Pulse Wave Stimulation in Alzheimer's patients.

ClinicalJuly 31, 2026

Trial on TMS for Early Alzheimer's Disease Shows Potential Efficacy

The trial aims to evaluate the safety and efficacy of personalized neuronavigated TMS in early Alzheimer's disease patients.

ClinicalJuly 29, 2026

Trial Initiated for CBD Effects on Alzheimer's Disease Biomarkers

A double-blind, randomized controlled trial is underway to evaluate the effects of CBD on Alzheimer's disease biomarkers and clinical measures.

ClinicalJuly 28, 2026

Study on Physical Activity's Impact on Self-esteem in Alzheimer's Patients

A study is evaluating the effectiveness of adapted physical activity on self-esteem and motivation in older adults with cognitive disorders, including Alzheimer's.

ClinicalJuly 25, 2026

Eisai Initiates Study on Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

Eisai Inc. is conducting a retrospective study to develop algorithms for identifying intracerebral hemorrhage and new-onset seizures in Alzheimer's patients using claims data linked to electronic health records.

RegulatoryJuly 23, 2026

FDA Grants Priority Review for LEQEMBI Supplement Application

The FDA has granted priority review status for the supplemental application of LEQEMBI (lecanemab-IRMB) submitted by Eisai Inc.

ClinicalJuly 20, 2026

Study on Sleep Intervention's Impact on Alzheimer's Disease Progression

A study is investigating the effects of time-in-bed restriction on sleep quality and cognitive function in older adults at risk for Alzheimer's disease.

ClinicalJuly 20, 2026

Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease

Merck is conducting a clinical trial to evaluate the efficacy and safety of MK-2214 in slowing tau protein accumulation in early Alzheimer's disease patients.

RegulatoryJuly 16, 2026

FDA Grants Priority Review for LEQEMBI Supplement Application

The FDA has granted priority review status for the supplemental application of LEQEMBI (lecanemab-IRMB) submitted by Eisai Inc.

RegulatoryJuly 14, 2026

FDA Approves First At-home Starting Dose for Leqembi in Alzheimer's Treatment

The FDA has approved a new starting dosage regimen for Leqembi, allowing for at-home administration.

ClinicalJuly 14, 2026

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

A Phase 3 study has been launched to assess the safety and efficacy of KarXT + KarX-EC for treating agitation in Alzheimer's patients.

ClinicalJuly 10, 2026

Network-Guided TMS Trial for Alzheimer's Behavioral Symptoms Initiated

A double-blind randomized controlled trial is underway to assess the safety and efficacy of personalized network-guided transcranial magnetic stimulation (TMS) for behavioral and psychological symptoms in Alzheimer's disease.

CompetitiveJuly 10, 2026

Lilly presents new Alzheimer's diagnostic and therapeutic data at AAIC 2026

Lilly will present new data on P-tau217 blood tests and insights from Kisunla trials at AAIC 2026.

ClinicalJuly 8, 2026

Hoffmann-La Roche initiates trial for trontinemab in early symptomatic Alzheimer's disease

A clinical trial is underway to evaluate the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease.

ClinicalJuly 7, 2026

Roche to present new Alzheimer’s data, including trontinemab and pTau217 blood test, at AAIC 2026

Roche will present new long-term data on trontinemab and the Elecsys pTau217 blood test at AAIC 2026, highlighting advancements in Alzheimer's diagnostics and treatment.

ClinicalJuly 7, 2026

Roche presents new Alzheimer’s data at AAIC 2026, highlighting trontinemab and blood tests

Roche will present new long-term data on trontinemab and the Elecsys pTau217 blood test at AAIC 2026.

ClinicalJuly 5, 2026

Teikoku Pharma initiates trial for DMTS in Alzheimer's-related agitation

Teikoku Pharma USA is evaluating the efficacy of Dexmedetomidine Transdermal Systems for treating agitation in Alzheimer's patients.

ClinicalJune 28, 2026

University of Bern Trials Remote Cognitive Training for Alzheimer's Disease

A study is underway to assess the feasibility and usability of a tablet-based cognitive training program for Alzheimer's disease.

ClinicalJune 26, 2026

Study on Deep Cervical Lymphovenous Anastomosis for Severe Alzheimer's Disease Initiated

A prospective study is underway to evaluate the efficacy and safety of deep cervical lymphovenous anastomosis in severe Alzheimer's patients.

ClinicalJune 17, 2026

Launch of Alzheimer's Disease Neuroimaging Initiative 4 to Validate Biomarkers

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) aims to validate biomarkers and improve clinical trial design for Alzheimer's disease.

ClinicalJune 17, 2026

ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals is launching a master protocol for three independent studies evaluating ACP-204 in Alzheimer's Disease Psychosis.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test designed to detect Alzheimer's disease pathology.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.

Relevant assets

Relevant companies

Recent signals(23)

Study on Transcranial Pulse Stimulation for Alzheimer's Disease Safety and Efficacy

Trial on TMS for Early Alzheimer's Disease Shows Potential Efficacy

Trial Initiated for CBD Effects on Alzheimer's Disease Biomarkers

Study on Physical Activity's Impact on Self-esteem in Alzheimer's Patients

Eisai Initiates Study on Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

FDA Grants Priority Review for LEQEMBI Supplement Application

Study on Sleep Intervention's Impact on Alzheimer's Disease Progression

Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease

FDA Grants Priority Review for LEQEMBI Supplement Application

FDA Approves First At-home Starting Dose for Leqembi in Alzheimer's Treatment

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

Network-Guided TMS Trial for Alzheimer's Behavioral Symptoms Initiated

Lilly presents new Alzheimer's diagnostic and therapeutic data at AAIC 2026

Hoffmann-La Roche initiates trial for trontinemab in early symptomatic Alzheimer's disease

Roche to present new Alzheimer’s data, including trontinemab and pTau217 blood test, at AAIC 2026

Roche presents new Alzheimer’s data at AAIC 2026, highlighting trontinemab and blood tests

Teikoku Pharma initiates trial for DMTS in Alzheimer's-related agitation

University of Bern Trials Remote Cognitive Training for Alzheimer's Disease

Study on Deep Cervical Lymphovenous Anastomosis for Severe Alzheimer's Disease Initiated

Launch of Alzheimer's Disease Neuroimaging Initiative 4 to Validate Biomarkers

ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Upcoming catalysts(1)

Eli Lilly — Donanemab

Therapeutic areas

Get signals before the market moves